NCT06127667 Brain Vascular and Neural Function Linked to Balance Across the Adult Lifespan
| NCT ID | NCT06127667 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Minnesota |
| Condition | Neurotypical |
| Study Type | INTERVENTIONAL |
| Enrollment | 102 participants |
| Start Date | 2024-10-15 |
| Primary Completion | 2028-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 102 participants in total. It began in 2024-10-15 with a primary completion date of 2028-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-arm, two-visit, non-randomized, cross sectional study identified as an intervention due to the use of a single bout of aerobic exercise to assess cerebrovascular function under the NIH rules. This study is not masked and its primary purpose is to develop a basic science understanding of the relationship between cerebrovascular health and balance control with aging. This study will involve 102 individuals classified as younger adults, middle-aged adults, and older adults who are neurotypical and cognitively normal. The primary outcome from a clinical trials perspective will be cerebrovascular response to a bout of aerobic exercise (i.e. change in cerebral blood flow with the performance of aerobic exercise on a recumbent stepper exercise machine). Non-interventional outcomes will be EEG measures of cortical activity and biomechanical kinetic and kinematic data recorded during standing balance reactions, as well as biological blood samples for genomic analysis.
Eligibility Criteria
Inclusion Criteria: * Age within the following 3 group age ranges, 21-30yo; middle-aged: 40-55yo; older: 65-95yo adults * the absence of major orthopedic disability * cognitively normal (MoCA score ≥ 26/30 in older adult group) * vision that is 20/40 or better with or without corrective lenses, (5) the ability to consent and communicate with researchers * English speaking * ability to stand for 3 minutes and walk 10 meters with or without an assistive device and without the assistance of another person. Exclusion Criteria: * insulin-dependent diabetes * peripheral neuropathy * myocardial infarction or symptoms of coronary artery disease within 2 years * congestive heart failure or class IV heart failure * any significant sensory impairment affecting balance or cognition; visual, vestibular, or auditory impairments.
Contact & Investigator
Jacqueline Palmer
PRINCIPAL INVESTIGATOR
University of Minnesota
Frequently Asked Questions
Who can join the NCT06127667 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 95 Years, studying Neurotypical. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06127667 currently recruiting?
Yes, NCT06127667 is actively recruiting participants. Contact the research team at brainsinmotion@umn.edu for enrollment information.
Where is the NCT06127667 trial being conducted?
This trial is being conducted at Minneapolis, United States.
Who is sponsoring the NCT06127667 clinical trial?
NCT06127667 is sponsored by University of Minnesota. The principal investigator is Jacqueline Palmer at University of Minnesota. The trial plans to enroll 102 participants.